Lutetium Lu 177 dotatate

(Lutathera)

Lutetium Lu 177 dotatate

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 370 MBq/mL (10 mCi/mL))
Drug ClassRadiolabeled somatostatin analogs
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.